A Study of Metabolic Agents Following Brain Radiation

Pilot Imaging Study for CNS Metabolism

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06150547

Enrollment

Registered

2023-11-29

Start date

2023-12-27

Completion date

2025-08-04

Last updated

2025-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CNS Malignancy

Brief summary

This study is being done to determine if CEST magnetic resonance imaging (MRI) and FDG PET are feasible techniques to detect metabolic differences between tumor and brain in patients with a brain tumor.

Interventions

DIAGNOSTIC_TESTFDG Positron Emission Tomography

Imaging using an FDG radioactive tracer to look at the head.

DIAGNOSTIC_TESTChemical Exchange Saturation Transfer Magnetic Resonance Imaging

A noninvasive diagnostic test for measuring biochemical changes in the brain, especially the presence of tumors.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Radiographic evidence or histopathologic confirmation of CNS malignancy, with or without prior resection. * Provide written informed consent for the current study. * Willing to undergo at least one MRI (and possibly more at PI discretion) with proton and/or phosphorus magnetic resonance spectroscopy analysis.

Exclusion criteria

* Vulnerable populations: pregnant or nursing women (Arm B exempt), prisoners, mentally handicapped. * Cardiac pacemaker or artificial heart valve * Metal plate, pin, or other metallic implant * Intrauterine device, such as Copper-7 IUD * Insulin or other drug pump * Non-titanium aneurysm clips * Previous gunshot wound * Cochlear implant or other hearing device * Employment history as a metalworker (had metal in eye) * Permanent (tattoo) eye-liner * For FDG-PET specifically: Fasting blood sugar level greater than 200mg/dl

Design outcomes

Primary

Measure	Time frame	Description
Number of subjects in whom glutamate metabolite is detected and measurable.	Baseline	Number of subjects in whom glutamate metabolite is detected and measurable via CEST MRI in tumor, brain, and/or the ventricular space.
Number of subjects in whom n-acetylaspartate (NAA) metabolite is detected and measurable.	Baseline	Number of subjects in whom n-acetylaspartate (NAA) metabolite is detected and measurable via CEST MRI in tumor, brain, and/or the ventricular space.

Secondary

Measure	Time frame	Description
Time required to perform the CEST MRI study and measure metabolites of interest	Duration of CEST MRI scan, approximately one to two hours.	Total time expressed in minutes required to perform the CEST MRI study and measure metabolites of interest.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026